Cost-effectiveness analysis of ramucirumab treatment for patients with hepatocellular carcinoma who progressed on sorafenib with α-fetoprotein concentrations of at least 400 ng/ml. [electronic resource]
Producer: 20210121Description: 347-352 p. digitalISSN:- 1941-837X
- Antibodies, Monoclonal, Humanized -- economics
- Antineoplastic Agents -- therapeutic use
- Carcinoma, Hepatocellular -- drug therapy
- Cost-Benefit Analysis
- Disease-Free Survival
- Humans
- Liver Neoplasms
- Markov Chains
- Sorafenib -- therapeutic use
- Treatment Outcome
- United States
- alpha-Fetoproteins -- administration & dosage
- Ramucirumab
No physical items for this record
Publication Type: Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.